Скачать или смотреть HIV Stribild Tablets - Hospital Scout

Stribild® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil (as fumarate) 245 mg), a once-daily single tablet regimen for the treatment of HIV, is available in the United Kingdom.

Stribild® was granted a license by the European Commission on May 27, 2013 for the treatment of HIV-1 infection in adult patients aged 18 and over who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to any of the product's three antiretroviral agents. "Treatment guidelines from the British HIV Association recommend HIV regimen simplification to help enhance patient adherence. This can keep the virus under control, which may improve long-term health benefits for patients," said Dr. Anton Pozniak, Director, HIV Service, Chelsea and Westminster Hospital, London. "In pivotal studies, once-daily Stribild was highly effective and generally well tolerated with a favorable safety profile, and is an important advance for HIV patients in the United Kingdom." The license is supported by 48-week data from two pivotal Phase 3 studies in which Stribild met its primary objective of non-inferiority compared to Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil (as fumarate) 245 mg) (Study 102) and to a regimen containing ritonavir-boosted atazanavir plus Truvada® (emtricitabine/tenofovir disoproxil (as fumarate)) (Study 103). The product has also been granted a license in the United States, Canada, Australia, South Korea, Japan and Turkey.

Stribild is the third single tablet HIV regimen developed by Gilead to become available in Europe. The first, Atripla, was granted a license in the European Union in 2007 and is marketed by Gilead in partnership with Bristol-Myers Squibb and Merck & Co. The second, Eviplera®▼ (emtricitabine 200mg/rilpivirine 25mg/tenofovir disoproxil (as fumarate) 245mg), is marketed by Gilead and Janssen R&D Ireland and received European marketing authorization in November 2011.

About Stribild®: Stribild contains four Gilead compounds in a complete once-daily, single tablet regimen: elvitegravir 150 mg; cobicistat 150 mg; emtricitabine 200 mg; and tenofovir disoproxil (as fumarate) 245 mg.

Hospital Scout http://www.hospitalscout.com
Unravel Travel TV http://www.unraveltravel.eu